Schwannosis: Role of gliosis and proteoglycan in human spinal cord injury

J. H. Bruce, Michael D Norenberg, S. Kraydieh, W. Puckett, Alexander Marcillo, W. Dalton Dietrich

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Schwannosis (aberrant proliferation of Schwann cells and nerve fibers) has been reported following spinal cord injury (SCI). In this study, we examined the incidence of schwannosis following human SCI, and investigated its relationship to gliosis. We found evidence of schwannosis in 32 out of 65 cases (48%) of human SCI that survived 24 h to 24 years after injury; this incidence rose to 82% in those patients who survived for more than 4 months. Schwannosis was not observed in cases that survived less than 4 months after injury. In affected cases, it was generally noted in areas that had low immunoreactivity for glial fibrillary acidic protein (GFAP), suggesting that reduced gliosis might have contributed to the aberrant proliferation of Schwann cells following SCI. Since chondroitin sulfate proteoglycan (CSPG) has been proposed to play a role in Schwann cell/glial interaction, we performed immunohistochemical staining for CSPG to investigate its potential relationship with schwannosis. CSPG in the injured cord was generally associated with the blood vessel walls, but was also sometimes noted in reactive astrocytes. In SCI with schwannosis, CSPG staining was more prominent and confined largely to the extracellular matrix and basal lamina of proliferating Schwann cells. Our study suggests that Schwann cells, which may have been displaced from spinal roots and introduced into the injured cord through a break in the pial surface, are capable of proliferating and producing CSPG, particularly in the setting of reduced gliosis. Since CSPG has been associated with inhibition of neurite outgrowth, its increased production by aberrant Schwann cells may impair spinal cord regeneration after injury.

Original languageEnglish
Pages (from-to)781-788
Number of pages8
JournalJournal of Neurotrauma
Volume17
Issue number9
StatePublished - Oct 14 2000

Fingerprint

Chondroitin Sulfate Proteoglycans
Gliosis
Schwann Cells
Proteoglycans
Spinal Cord Injuries
Wounds and Injuries
Spinal Cord Regeneration
Staining and Labeling
Spinal Nerve Roots
Glial Fibrillary Acidic Protein
Incidence
Nerve Fibers
Basement Membrane
Cell Communication
Neuroglia
Astrocytes
Extracellular Matrix
Blood Vessels

Keywords

  • Astrogliosis
  • Chondroitin sulfate proteoglycan
  • Glial fibrillary acidic protein
  • Schwannosis
  • Spinal cord injury

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Schwannosis : Role of gliosis and proteoglycan in human spinal cord injury. / Bruce, J. H.; Norenberg, Michael D; Kraydieh, S.; Puckett, W.; Marcillo, Alexander; Dalton Dietrich, W.

In: Journal of Neurotrauma, Vol. 17, No. 9, 14.10.2000, p. 781-788.

Research output: Contribution to journalArticle

Bruce, JH, Norenberg, MD, Kraydieh, S, Puckett, W, Marcillo, A & Dalton Dietrich, W 2000, 'Schwannosis: Role of gliosis and proteoglycan in human spinal cord injury', Journal of Neurotrauma, vol. 17, no. 9, pp. 781-788.
Bruce, J. H. ; Norenberg, Michael D ; Kraydieh, S. ; Puckett, W. ; Marcillo, Alexander ; Dalton Dietrich, W. / Schwannosis : Role of gliosis and proteoglycan in human spinal cord injury. In: Journal of Neurotrauma. 2000 ; Vol. 17, No. 9. pp. 781-788.
@article{2cd5ad5cd8864eed85d9f3b446270e14,
title = "Schwannosis: Role of gliosis and proteoglycan in human spinal cord injury",
abstract = "Schwannosis (aberrant proliferation of Schwann cells and nerve fibers) has been reported following spinal cord injury (SCI). In this study, we examined the incidence of schwannosis following human SCI, and investigated its relationship to gliosis. We found evidence of schwannosis in 32 out of 65 cases (48{\%}) of human SCI that survived 24 h to 24 years after injury; this incidence rose to 82{\%} in those patients who survived for more than 4 months. Schwannosis was not observed in cases that survived less than 4 months after injury. In affected cases, it was generally noted in areas that had low immunoreactivity for glial fibrillary acidic protein (GFAP), suggesting that reduced gliosis might have contributed to the aberrant proliferation of Schwann cells following SCI. Since chondroitin sulfate proteoglycan (CSPG) has been proposed to play a role in Schwann cell/glial interaction, we performed immunohistochemical staining for CSPG to investigate its potential relationship with schwannosis. CSPG in the injured cord was generally associated with the blood vessel walls, but was also sometimes noted in reactive astrocytes. In SCI with schwannosis, CSPG staining was more prominent and confined largely to the extracellular matrix and basal lamina of proliferating Schwann cells. Our study suggests that Schwann cells, which may have been displaced from spinal roots and introduced into the injured cord through a break in the pial surface, are capable of proliferating and producing CSPG, particularly in the setting of reduced gliosis. Since CSPG has been associated with inhibition of neurite outgrowth, its increased production by aberrant Schwann cells may impair spinal cord regeneration after injury.",
keywords = "Astrogliosis, Chondroitin sulfate proteoglycan, Glial fibrillary acidic protein, Schwannosis, Spinal cord injury",
author = "Bruce, {J. H.} and Norenberg, {Michael D} and S. Kraydieh and W. Puckett and Alexander Marcillo and {Dalton Dietrich}, W.",
year = "2000",
month = "10",
day = "14",
language = "English",
volume = "17",
pages = "781--788",
journal = "Journal of Neurotrauma",
issn = "0897-7151",
publisher = "Mary Ann Liebert Inc.",
number = "9",

}

TY - JOUR

T1 - Schwannosis

T2 - Role of gliosis and proteoglycan in human spinal cord injury

AU - Bruce, J. H.

AU - Norenberg, Michael D

AU - Kraydieh, S.

AU - Puckett, W.

AU - Marcillo, Alexander

AU - Dalton Dietrich, W.

PY - 2000/10/14

Y1 - 2000/10/14

N2 - Schwannosis (aberrant proliferation of Schwann cells and nerve fibers) has been reported following spinal cord injury (SCI). In this study, we examined the incidence of schwannosis following human SCI, and investigated its relationship to gliosis. We found evidence of schwannosis in 32 out of 65 cases (48%) of human SCI that survived 24 h to 24 years after injury; this incidence rose to 82% in those patients who survived for more than 4 months. Schwannosis was not observed in cases that survived less than 4 months after injury. In affected cases, it was generally noted in areas that had low immunoreactivity for glial fibrillary acidic protein (GFAP), suggesting that reduced gliosis might have contributed to the aberrant proliferation of Schwann cells following SCI. Since chondroitin sulfate proteoglycan (CSPG) has been proposed to play a role in Schwann cell/glial interaction, we performed immunohistochemical staining for CSPG to investigate its potential relationship with schwannosis. CSPG in the injured cord was generally associated with the blood vessel walls, but was also sometimes noted in reactive astrocytes. In SCI with schwannosis, CSPG staining was more prominent and confined largely to the extracellular matrix and basal lamina of proliferating Schwann cells. Our study suggests that Schwann cells, which may have been displaced from spinal roots and introduced into the injured cord through a break in the pial surface, are capable of proliferating and producing CSPG, particularly in the setting of reduced gliosis. Since CSPG has been associated with inhibition of neurite outgrowth, its increased production by aberrant Schwann cells may impair spinal cord regeneration after injury.

AB - Schwannosis (aberrant proliferation of Schwann cells and nerve fibers) has been reported following spinal cord injury (SCI). In this study, we examined the incidence of schwannosis following human SCI, and investigated its relationship to gliosis. We found evidence of schwannosis in 32 out of 65 cases (48%) of human SCI that survived 24 h to 24 years after injury; this incidence rose to 82% in those patients who survived for more than 4 months. Schwannosis was not observed in cases that survived less than 4 months after injury. In affected cases, it was generally noted in areas that had low immunoreactivity for glial fibrillary acidic protein (GFAP), suggesting that reduced gliosis might have contributed to the aberrant proliferation of Schwann cells following SCI. Since chondroitin sulfate proteoglycan (CSPG) has been proposed to play a role in Schwann cell/glial interaction, we performed immunohistochemical staining for CSPG to investigate its potential relationship with schwannosis. CSPG in the injured cord was generally associated with the blood vessel walls, but was also sometimes noted in reactive astrocytes. In SCI with schwannosis, CSPG staining was more prominent and confined largely to the extracellular matrix and basal lamina of proliferating Schwann cells. Our study suggests that Schwann cells, which may have been displaced from spinal roots and introduced into the injured cord through a break in the pial surface, are capable of proliferating and producing CSPG, particularly in the setting of reduced gliosis. Since CSPG has been associated with inhibition of neurite outgrowth, its increased production by aberrant Schwann cells may impair spinal cord regeneration after injury.

KW - Astrogliosis

KW - Chondroitin sulfate proteoglycan

KW - Glial fibrillary acidic protein

KW - Schwannosis

KW - Spinal cord injury

UR - http://www.scopus.com/inward/record.url?scp=0033806969&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033806969&partnerID=8YFLogxK

M3 - Article

C2 - 11011818

AN - SCOPUS:0033806969

VL - 17

SP - 781

EP - 788

JO - Journal of Neurotrauma

JF - Journal of Neurotrauma

SN - 0897-7151

IS - 9

ER -